{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:19:31Z","timestamp":1792790371125,"version":"4.5.0"},"posted":{"date-parts":[[2026,10,1]]},"group-title":"Pharmacology and Toxicology","reference-count":36,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"award":["U54DK137314"],"award-info":[{"award-number":["U54DK137314"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P30DK89503"],"award-info":[{"award-number":["P30DK89503"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]},{"award":["U2CDK129445"],"award-info":[{"award-number":["U2CDK129445"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]},{"award":["TL1DK136046"],"award-info":[{"award-number":["TL1DK136046"]}],"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}]},{"award":["5-COE-2019-861-S-B"],"award-info":[{"award-number":["5-COE-2019-861-S-B"]}],"id":[{"id":"https:\/\/ror.org\/02j6fbg68","id-type":"ROR","asserted-by":"publisher"}]},{"name":"American Heart Association","award":["26CDA1601970"],"award-info":[{"award-number":["26CDA1601970"]}],"id":[{"id":"https:\/\/ror.org\/013kjyp64","id-type":"ROR","asserted-by":"crossref"}]},{"award":["I01CX002684-01"],"award-info":[{"award-number":["I01CX002684-01"]}],"id":[{"id":"https:\/\/ror.org\/05rsv9s98","id-type":"ROR","asserted-by":"publisher"}]},{"name":"National Heart Lung and Blood Institute","award":["1R61HL177474-01"],"award-info":[{"award-number":["1R61HL177474-01"]}],"id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular mortality and chronic kidney disease (CKD) progression in cardiovascular-kidney-metabolic (CKM) syndrome, but this benefit derives primarily from reductions in heart failure and cardiovascular mortality rather than in atherothrombotic events. Sotagliflozin, which inhibits both intestinal SGLT1 and renal SGLT2, is the only drug in this class shown to lower rates of myocardial infarction and stroke in CKD. However, its mechanism remains unclear, and its effectiveness in non-diabetic CKD has not been studied. We hypothesized that dual SGLT1\/2 inhibition reprograms systemic substrate utilization toward fatty acid oxidation, which may partially account for this protective effect.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    CKD was induced in male low-density lipoprotein receptor-deficient mice by 5\/6 nephrectomy. Sham and CKD mice received a high-fat diet and drinking water containing sotagliflozin, empagliflozin, or vehicle for 16 weeks, at doses that produced equivalent fractional excretion of glucose. We quantified atherosclerosis\n                    <jats:italic>en face<\/jats:italic>\n                    and in the aortic sinus. Indirect calorimetry, echocardiography, hepatic RNA sequencing, plasma acylcarnitine profiling, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    deuterium labeling of palmitate were performed.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    At matched levels of glucosuria and plasma total cholesterol, sotagliflozin decreased body mass, atherosclerosis burden, triglycerides, and TNF-\u03b1 more than empagliflozin, and raised postprandial total GLP-1 approximately 3-fold, while both drugs similarly improved albuminuria and diastolic function. Sotagliflozin increased energy expenditure independent of body mass and lowered respiratory exchange ratio despite compensatory hyperphagia. Sotagliflozin reduced hepatic lipogenic genes and\n                    <jats:italic>de novo<\/jats:italic>\n                    lipogenic flux, while increasing \u03b2-oxidation and ketogenesis; empagliflozin only activated the oxidative pathway.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In experimental CKM syndrome, dual SGLT1\/2 inhibition reduces atherosclerosis and metabolic syndrome more effectively than selective SGLT2 inhibition and is associated with reprogramming of hepatic lipid metabolism. These results suggest that sotagliflozin could be an attractive candidate for mitigating atherosclerotic risk in non-diabetic CKD.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Graphical Abstract<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"754502v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.25.754502","type":"posted-content","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:50:23Z","timestamp":1790905823000},"source":"Crossref","is-referenced-by-count":0,"title":["Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3851-1039","authenticated-orcid":false,"given":"Keith","family":"Saum","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie","family":"Steward","sequence":"additional","affiliation":[{"name":"The University of Toledo College of Medicine and Life Sciences, Toledo, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Kayampilly","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alethia","family":"Dixon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Abdel-Latif","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI, USA"},{"name":"Ann Arbor Veteran Affairs Healthcare System, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramaniam","family":"Pennathur","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, USA"},{"name":"Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026100604351098000_2026.09.25.754502v1.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686"},{"key":"2026100604351098000_2026.09.25.754502v1.2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070714"},{"key":"2026100604351098000_2026.09.25.754502v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001184"},{"key":"2026100604351098000_2026.09.25.754502v1.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.6892"},{"key":"2026100604351098000_2026.09.25.754502v1.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067626"},{"key":"2026100604351098000_2026.09.25.754502v1.6","doi-asserted-by":"crossref","unstructured":"Ndumele CE , Rodriguez F , Dixon DL , Khan SS , Mukherjee D , Bajaj M , Bangalore S , Bozkurt B , Breathett K , Clarke SL , et al. 2026 AHA\/ACC\/ADA\/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4).","DOI":"10.1161\/CIRCULATIONAHA.126.080897"},{"key":"2026100604351098000_2026.09.25.754502v1.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069568"},{"key":"2026100604351098000_2026.09.25.754502v1.8","doi-asserted-by":"crossref","unstructured":"Rivera FB , Cruz LLA , Magalong JV , Ruyeras JMMJ , Aparece JP , Bantayan NRB , Lara-Breitinger K , Gulati M . Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. American Journal of Preventive Cardiology. 2024;18:100679.","DOI":"10.1016\/j.ajpc.2024.100679"},{"issue":"8","key":"2026100604351098000_2026.09.25.754502v1.9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","year":"2024","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"2","key":"2026100604351098000_2026.09.25.754502v1.10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/ajpcell.00328.2011","article-title":"Structural selectivity of human SGLT inhibitors","volume":"302","year":"2012","journal-title":"American journal of physiology. Cell physiology"},{"issue":"9","key":"2026100604351098000_2026.09.25.754502v1.11","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.2337\/dc21-2166","article-title":"Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"2026100604351098000_2026.09.25.754502v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.07.061"},{"key":"2026100604351098000_2026.09.25.754502v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2030186"},{"issue":"4","key":"2026100604351098000_2026.09.25.754502v1.14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial","volume":"13","year":"2025","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"2026100604351098000_2026.09.25.754502v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2026.100975"},{"key":"2026100604351098000_2026.09.25.754502v1.16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.000559"},{"key":"2026100604351098000_2026.09.25.754502v1.17","doi-asserted-by":"crossref","unstructured":"Mathew A V. , Zeng L , Atkins KB , Sadri KN , Byun J , Fujiwara H , Reddy P , Pennathur S . Deletion of bone marrow myeloperoxidase attenuates chronic kidney disease accelerated atherosclerosis. Journal of Biological Chemistry. 2021;296.","DOI":"10.1074\/jbc.RA120.014095"},{"issue":"734","key":"2026100604351098000_2026.09.25.754502v1.18","first-page":"1","article-title":"Metabolomic Profiling of Arginine Metabolome Links Altered Methylation to Chronic Kidney Disease Accelerated Atherosclerosis","volume":"14","year":"2015","journal-title":"Journal of Proteomics & Bioinformatics"},{"key":"2026100604351098000_2026.09.25.754502v1.19","doi-asserted-by":"crossref","unstructured":"Daugherty A , Tall AR , Daemen MJAP , Falk E , Fisher EA , Garc\u00eda-Carde\u00f1a G , Lusis AJ , Owens AP , Rosenfeld ME , Virmani R . Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Circulation Research. 2017:RES.0000000000000169.","DOI":"10.1161\/RES.0000000000000169"},{"issue":"19","key":"2026100604351098000_2026.09.25.754502v1.20","doi-asserted-by":"crossref","first-page":"e188933","DOI":"10.1172\/JCI188933","article-title":"SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress","volume":"135","year":"2025","journal-title":"The Journal of Clinical Investigation"},{"key":"2026100604351098000_2026.09.25.754502v1.21","doi-asserted-by":"crossref","unstructured":"Osataphan S , Macchi C , Singhal G , Chimene-Weiss J , Sales V , Kozuka C , Dreyfuss JM , Pan H , Tangcharoenpaisan Y , Morningstar J , et al. SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms. JCI insight. 2019;4(5).","DOI":"10.1172\/jci.insight.123130"},{"key":"2026100604351098000_2026.09.25.754502v1.22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061732"},{"key":"2026100604351098000_2026.09.25.754502v1.23","doi-asserted-by":"crossref","unstructured":"Neuen BL , Fletcher RA , Anker SD , Bhatt DL , Butler J , Cherney DZI , Docherty KF , Inzucchi SE , Jardine MJ , Mahaffey KW , et al. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis. JAMA. 2026;335(3).","DOI":"10.1001\/jama.2025.20834"},{"issue":"1","key":"2026100604351098000_2026.09.25.754502v1.24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1681\/ASN.2010080888","article-title":"The Sweet Pee model for Sglt2 mutation","volume":"22","year":"2011","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"1","key":"2026100604351098000_2026.09.25.754502v1.25","first-page":"783","article-title":"Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet","volume":"7","year":"2019","journal-title":"BMJ Open Diabetes Research and Care"},{"key":"2026100604351098000_2026.09.25.754502v1.26","doi-asserted-by":"publisher","DOI":"10.2337\/db15-1356"},{"key":"2026100604351098000_2026.09.25.754502v1.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.00001.x"},{"issue":"5513","key":"2026100604351098000_2026.09.25.754502v1.28","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1126\/science.1056843","article-title":"Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2","volume":"291","year":"2001","journal-title":"Science (New York, N.Y.)"},{"issue":"9943","key":"2026100604351098000_2026.09.25.754502v1.29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","year":"2014","journal-title":"The Lancet"},{"key":"2026100604351098000_2026.09.25.754502v1.30","doi-asserted-by":"crossref","unstructured":"Saum KL , Pennathur S , Kanter JE . Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD. Circulation research. 2026;138(12).","DOI":"10.1161\/CIRCRESAHA.126.327361"},{"key":"2026100604351098000_2026.09.25.754502v1.31","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017030350"},{"issue":"7","key":"2026100604351098000_2026.09.25.754502v1.32","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.jlr.2026.101072","article-title":"Plasma acylcarnitine profiling reveals heart failure-specific fatty acid oxidation signature in chronic kidney disease","volume":"67","year":"2026","journal-title":"Journal of Lipid Research"},{"key":"2026100604351098000_2026.09.25.754502v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3804"},{"issue":"1","key":"2026100604351098000_2026.09.25.754502v1.34","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41598-024-52331-w","article-title":"Effect of pharmacological selectivity of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes: a meta-analysis","volume":"14","year":"2024","journal-title":"Scientific Reports"},{"key":"2026100604351098000_2026.09.25.754502v1.35","doi-asserted-by":"publisher","DOI":"10.2337\/db11-1029"},{"issue":"10","key":"2026100604351098000_2026.09.25.754502v1.36","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.numecd.2021.06.002","article-title":"Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials. Nutrition","volume":"31","year":"2021","journal-title":"Metabolism and Cardiovascular Diseases"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.25.754502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:35:24Z","timestamp":1791286524000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.25.754502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":36,"URL":"https:\/\/doi.org\/10.64898\/2026.09.25.754502","relation":{},"subject":[],"published":{"date-parts":[[2026,10,1]]},"subtype":"preprint"}}